Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
James R. Berenson(Oncotherapeutics (United States)), Debra Mayo(Teva Pharmaceuticals (United States)), Tarun Kewalramani(Memorial Sloan Kettering Cancer Center), Edward J. Gorak, Stephen J. Noga, Ori Yellin, Youram Nassir, Donald Gravenor, Dipti Patel‐Donnelly(Orthopaedic Research of Virginia), Alberto Bessudo(California Cancer Associates for Research and Excellence), Robert S. Siegel(University of California, San Diego), Ralph V. Boccia(Center for Cancer and Blood Disorders), Regina A. Swift(Institute for Myeloma & Bone Cancer Research)
Cited by 53
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425